Loading…
Allarity Therapeutics, Inc. is projected to rise to $2.55 by 2027, a +48% move from its current price of $1.73. ALLR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.65 | $1.73 | $1.81 | -0.12% |
| May 30 | $1.61 | $1.73 | $1.85 | -0.25% |
| May 31 | $1.58 | $1.72 | $1.87 | -0.37% |
| Jun 1 | $1.56 | $1.72 | $1.90 | -0.49% |
| Jun 2 | $1.54 | $1.72 | $1.92 | -0.62% |
| Jun 3 | $1.52 | $1.72 | $1.93 | -0.74% |
| Jun 4 | $1.51 | $1.72 | $1.95 | -0.86% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.51 | $1.72 | $1.95 | -0.86% |
| Week 2 | $1.42 | $1.70 | $2.04 | -1.71% |
| Week 3 | $1.35 | $1.69 | $2.11 | -2.56% |
| Week 4 | $1.29 | $1.67 | $2.16 | -3.40% |
| Week 5 | $1.24 | $1.66 | $2.21 | -4.23% |
| Week 6 | $1.20 | $1.64 | $2.25 | -5.05% |
| Week 7 | $1.16 | $1.63 | $2.29 | -5.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Allarity Therapeutics, Inc. is a clinical-stage healthcare company focused on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. It pursues personalized cancer treatment using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc.
is headquartered in Tarpon Springs, Florida.
Allarity Therapeutics, Inc. (ALLR) is a healthcare company currently trading at $1.77 with a market capitalization of $28.16M and a market rank of 4834. The near-term forecast projects a path from 2026 to 2050 with rising averages and bullish sentiment in the longer term.
The 2026 average price is $1.77, rising to $2.81 by 2030 and reaching $11.47 by 2050, with corresponding ROIs of 0%, 58.5%, 261.2%, and 548.3% respectively. The stock exhibits bullish technicals, supported by a high RSI and positive momentum indicators.
A major floor 53.2% below — a decisive break under it would weaken the trend.
The nearest floor, 28.9% below — buyers have tended to step in here.
Price is pressing into resistance (2.3% away) — a breakout level to watch.
A major ceiling 22.4% above — clearing it would confirm fresh momentum.
Key ALLR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALLR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.67 | Buy | $1.67 | Buy |
| MA 10 | $1.57 | Buy | $1.60 | Buy |
| MA 20 | $1.50 | Buy | $1.52 | Buy |
| MA 50 | $1.32 | Buy | $1.38 | Buy |
| MA 100 | $1.20 | Buy | $1.33 | Buy |
| MA 200 | $1.26 | Buy | $369.96 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.11 | Neutral |
| Stoch RSI (14) | 58.83 | Neutral |
| CCI (20) | 135.48 | Buy |
| Williams %R (14) | -9.52 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 11.61 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 90.48 | Sell |
| TRIX (15) | 0.89 | Buy |
| Awesome (5,34) | 0.25 | Buy |
| Ultimate (7,14,28) | 74.92 | Sell |
| Momentum (10) | 0.21 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.79 | Sell |
| ADX (14) | 22.15 | Buy |
| ATR (14) | 0.07 | Info |
In the near term, the technical picture is bullish with RSI(14) at 70. The stock price is above the 50-day simple moving average at $1.31 and above the 200-day simple moving average at $1.26. The 30-day price range spans from $1.27 to $2.47, indicating upside potential within a relatively tight window.
On a near-term basis, support sits at $1.19 and resistance at $1.77, offering a defined path if momentum persists.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.81 | $1.73 | $2.47 | 0% | Neutral | |
| $1.87 | $2.55 | $3.76 | +48% | Bullish | |
| $1.74 | $2.50 | $3.90 | +45% | Bullish | |
| $1.73 | $2.61 | $4.24 | +51% | Bullish | |
| $1.76 | $2.76 | $4.66 | +59% | Bullish | |
| $1.48 | $2.40 | $4.20 | +39% | Bullish | |
| $1.86 | $3.14 | $5.64 | +82% | Bullish | |
| $2.31 | $4.04 | $7.44 | +133% | Bullish | |
| $2.26 | $4.09 | $7.71 | +136% | Bullish | |
| $2.42 | $4.53 | $8.73 | +162% | Bullish | |
| $2.83 | $6.20 | $13.05 | +258% | Bullish | |
| $4.99 | $11.08 | $25.48 | +540% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.81 | $1.73 | $2.05 | +0.00% |
| June 2026 | $1.38 | $1.65 | $2.04 | -4.47% |
| July 2026 | $1.27 | $1.55 | $1.95 | -6.47% |
| August 2026 | $1.31 | $1.61 | $2.07 | +4.13% |
| September 2026 | $1.34 | $1.67 | $2.17 | +3.53% |
| October 2026 | $1.29 | $1.61 | $2.13 | -3.29% |
| November 2026 | $1.32 | $1.66 | $2.22 | +3.00% |
| December 2026 | $1.44 | $1.83 | $2.47 | +10.19% |
Click any year to see its month-by-month ALLR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ALLR could reach as high as $2.47, with a base case around $1.73 and support toward $0.81 — roughly 0% from $1.73. Price action looks broadly range-bound.
Expect ALLR to range from $1.87 to $3.76 through 2027. The $2.55 average target implies a +48% move from current prices. That is up +48% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The ALLR price prediction for 2028 points to an average of $2.50 (low $1.74, high $3.90) — a potential gain of +45% on today's $1.73. Momentum favours further upside here.
In 2029, ALLR is projected to trade between $1.73 and $4.24, averaging $2.61 — a potential gain of +51% from today's $1.73. That is up +4% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Allarity Therapeutics, Inc.'s 2030 outlook centres on $2.76, within a $1.76 to $4.66 range. That is up +6% on the projected 2029 average. That marks a +59% change versus current levels. Momentum favours further upside here.
By 2031, ALLR could reach as high as $4.20, with a base case around $2.40 and support toward $1.48 — roughly +39% from $1.73. Buyers look set to stay in control over this stretch.
Expect ALLR to range from $1.86 to $5.64 through 2032. The $3.14 average target implies a +82% move from current prices. That is up +31% on the projected 2031 average. Momentum favours further upside here.
The ALLR price prediction for 2033 points to an average of $4.04 (low $2.31, high $7.44) — a potential gain of +133% on today's $1.73. Buyers look set to stay in control over this stretch.
In 2034, ALLR is projected to trade between $2.26 and $7.71, averaging $4.09 — a potential gain of +136% from today's $1.73. That is up +1% on the projected 2033 average. Momentum favours further upside here.
Allarity Therapeutics, Inc.'s 2035 outlook centres on $4.53, within a $2.42 to $8.73 range. That is up +11% on the projected 2034 average. That marks a +162% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ALLR could reach as high as $13.05, with a base case around $6.20 and support toward $2.83 — roughly +258% from $1.73. Momentum favours further upside here.
Expect ALLR to range from $4.99 to $25.48 through 2050. The $11.08 average target implies a +540% move from current prices. That is up +79% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ALLR today (≈ 578.034682 ALLR) could be worth
$6,404.1
+$5,404.1 (+540%) by 2050 · US Dollar
Based on the average projected ALLR price of $11.08 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALLRwould be worth at today's price.
$1,000 invested in ALLR on May 27, 2025 (≈ 1,052.631592 ALLR) would be worth
$1,821.05
+$821.05 (+82.1%) today · 1.82× · US Dollar
Based on a ALLR entry price of $0.95 vs. today's $1.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.49 | $1,161.07 | +16.1% |
| 1 month ago | $1.37 | $1,262.77 | +26.3% |
| 3 months ago | $0.995 | $1,738.69 | +73.9% |
| 6 months ago | $1.33 | $1,300.75 | +30.1% |
| 1 year ago | $0.95 | $1,821.05 | +82.1% |
| All time (4.4y) ago | $8,820,000 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALLR forecast.
Our base-case forecast reaches $3.50 around 2033.
Implied market cap at $3.50: $55.69M
Looking further out, the forecast outlines a clear upward trajectory with several key milestones. For 2026, the avg price is $1.77 with a min of $0.81 and a max of $2.58 and a 0% ROI, signaling a neutral stance. By 2030, the avg rises to $2.81 with a max of $4.80 and a min of $1.76, delivering a 58.5% ROI in a bullish context.
The trajectory continues through 2031–2035 with progressive increases in avg values (e.g., 2031 $2.46, 2032 $3.23, 2033 $4.16, 2034 $4.24, 2035 $4.66) and steadily rising ROIs, culminating in 2035 at 163.1% with bullish sentiment. The long-range 2040 forecast shows an avg of $6.39, a min of $2.88, a max of $13.68, and a 261.2% ROI, continuing the bullish view. By 2050, the avg is projected to $11.47, with a max of $26.39 and a min of $5.16, reflecting a 548.3% ROI.
While these figures indicate substantial upside, they are estimates and not guarantees, and are subject to market conditions and other uncertainties.
Tap a question to reveal the answer.
The forecast shows a 2030 avg of $2.81, with a min of $1.76 and a max of $4.80, and a 58.5% ROI; sentiment is bullish.
The forecast suggests bullish sentiment from 2027 onward, with rising average prices and positive ROIs (e.g., 2030 ROI 58.5%, 2040 ROI 261.2%, 2050 ROI 548.3%). However, these are estimates, not guarantees, and actual results may vary.
Yes. The 2040 max is $13.68 and the 2050 max is $26.39, while the 2050 avg is $11.47, indicating the potential to surpass $10 in the longer term.
Current price is $1.77 and market cap is $28.16M.
The 30-day price range is $1.27 to $2.47, RSI(14) is 70, SMA50 is $1.31, SMA200 is $1.26, with support at $1.19 and resistance at $1.77. Annualized volatility is 100%.
Allarity Therapeutics, Inc. Community Discussion
0Share your Allarity Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.